Xenetic Biosciences, Inc. XBIO 深 滬
等待開盤 10-09 09:30:00 美东时间
10.34
+6.050
+141.03%
華盛通- 最 高13.93
- 今 開12.00
- 成交量 4620.31万股
- 最 低 9.34
- 昨 收 4.29
- 總市值 1594.53万
- 52周最高 13.93
- 市盈率 靜 --
- 換手率 2996.11%
- 52周最低 2.20
- 委 比 -87.50%
- 總股本 154.21万
- 歷史最高 1074.00
- 量 比 670.12
- 振 幅 106.99%
- 歷史最低 2.20
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
今天 01:06
Nasdaq Gains 150 Points; US Mortgage Applications Decline
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more ...
10-08 22:22
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Confluent Inc (NASDAQ:CFLT) rose sharply in pre-market trading. Confl...
10-08 16:43
Xenetic Biosciences reports Q2 results
Xenetic Biosciences press release (NASDAQ:XBIO): Q2 Net loss for the quarter ended June 30, 2025 was approximately $0.7 million. Research & development expenses for the three months ended June 30, 202...
08-13 22:16
Xenetic Biosciences Q2 EPS $(0.45) Beats $(0.65) Estimate, Sales $589.897K Miss $720.000K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.65) by 30.77 percent. This is a 45.78 percent increase over losses of $(0.83) per share
08-13 20:09
Xenetic Biosciences Reports Improved Financial Performance
Xenetic Biosciences, Inc. ( ($XBIO) ) has released its Q2 earnings. Here is a b...
08-13 12:32
Xenetic Biosciences Announces First Patient Dosing In Exploratory Clinical Study Of Systemic DNase I In Combination With FOLFIRINOX For Advanced Or Metastatic Pancreatic Cancer
Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNessCompany evaluating systemic recombinant human DNase I (DNase I) in combination with
07-08 21:04
抢滩华贸黄金地段 迪桑特想复刻始祖鸟
转自：北京商报 高端运动品牌迪桑特在华迈出关键一步。北京商报记者从华贸中心处获悉，迪桑特已正式接手北京华贸中心原阿玛尼旗舰店1400平方米黄金铺位，创下...
06-20 00:29
Xenetic Biosciences reports Q1 results
Xenetic Biosciences press release (NASDAQ:XBIO): Q1 Net loss was approximately $0.9 million. Revenue increased by approximately $0.1 million, or 16.1%, to approximately $0.6 million during the three m...
05-14 20:21
Xenetic Biosciences Q1 EPS $(0.59) Beats $(0.72) Estimate, Sales $593.26K Miss $670.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.72) by 18.06 percent. This is a 24.36 percent increase over losses of $(0.78) per share
05-14 05:58
